Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma

Inclusion Criteria: * Histologically or cytologically confirmed sarcoma, including any of the following neoplastic subtypes: * Giant hemangioma * Angiosarcoma (including epithelioid hemangioendothelioma) * Malignant peripheral nerve sheath tumor * Leiomyosarcoma (closed to accrual as of 11/29/06) * High-grade undifferentiated pleomorphic sarcoma (i.e., malignant fibrous histiocytoma \[including myxofibrosarcoma\]) (closed to accrual as of 11/29/06) * Synovial sarcoma (closed to accrual as of 11/29/06) * Carcinosarcoma (closed to accrual as of 11/29/06) * Metastatic, locally advanced, or locally recurrent disease * Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan * Lesions in a previously irradiated area may be considered measurable provided there is evidence of subsequent disease progression that cannot be attributed to necrosis or bleeding * No gastrointestinal stromal tumor * No known brain metastases * Performance status - ECOG 0-2 * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * No evidence of bleeding diathesis * Bilirubin ≤ 1.5 mg/dL * INR ≤ 1.5 * AST and ALT ≤ 2.5 times upper limit of normal * Creatinine ≤ 1.5 mg/dL * No symptomatic congestive heart failure * No unstable angina pectoris * No cardiac arrhythmia * No uncontrolled hypertension * No history of allergic reaction to compounds of similar chemical or biologic composition to sorafenib * No known HIV positivity * No active or ongoing infection * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No psychiatric illness or social situation that would preclude study compliance * No swallowing dysfunction that would preclude the swallowing of tablets * Other malignancies allowed provided sarcoma is the primary disease requiring treatment * No other uncontrolled illness * No more than 1 prior chemotherapy regimen for recurrent or metastatic disease (≤ 3 regimens for angiosarcoma or malignant peripheral nerve sheath tumor) * Adjuvant chemotherapy completed \> 1 year prior to study entry is not considered a line of prior treatment * More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) * At least 3 weeks since prior radiotherapy * Recovered from prior antitumor therapy * Alopecia allowed * No prior sorafenib * No prior small molecule inhibitors of MAPK signaling intermediates * No concurrent therapeutic anticoagulation * Prophylactic anticoagulation (i.e., low-dose warfarin) of venous or arterial devices allowed provided requirements for PT, INR, or PTT requirements are met * No other concurrent investigational agents * No concurrent cytochrome P450 enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, or phenobarbital) * No concurrent rifampin or Hypericum perforatum (St. John's wort)